ANI Pharmaceuticals, Inc. officer Stephen Carey filed a Form 144 notice on October 29, 2026, disclosing a proposed sale of 8,550 shares of common stock through Morgan Stanley Smith Barney LLC.

Key Highlights

  • Proposed seller: Stephen Carey, an officer of ANI Pharmaceuticals, Inc.
  • Shares proposed for sale: 8,550 shares of common stock, with an aggregate market value of $613,120.50.
  • Source of shares: Restricted stock awards acquired from the issuer, with shares acquired on March 31, 2021 and vesting through April 10, 2021, according to the filing's remarks.
  • Approximate date of sale: October 29, 2026, to be executed through NASDAQ via Morgan Stanley Smith Barney LLC Executive Financial Services.
  • Trading plan: The filing indicates reliance on a Rule 10b5-1 plan adopted on March 6, 2026.
  • Prior sales under plan: 2,850 shares sold on September 29, 2026 for gross proceeds of $208,045.44, and 2,850 shares sold on August 31, 2026 for gross proceeds of $207,475.16.
  • Total shares outstanding: 22,959,488 shares of common stock, as reported in the filing.

Stephen Carey's Proposed Rule 144 Share Sale at ANI Pharmaceuticals

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Stephen Carey, identified as an officer of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), has provided notice of a proposed sale of 8,550 shares of the company's common stock. The aggregate market value of the proposed sale is listed as $613,120.50. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, as the designated broker for the transaction.

The filing discloses that the shares to be sold were originally acquired as restricted stock awards from the issuer. The remarks section states: "The securities to be sold were acquired upon the vesting of restricted stock awards during the period of 03/31/2021 through 04/10/2021." The acquisition date listed in the securities table is March 31, 2021, with a payment date also of March 31, 2021, and the nature of payment noted as "N/A." Carey indicated the sale relies on a written trading plan adopted under Rule 10b5-1 on March 6, 2026.

The filing also discloses prior sales by Carey during the three months preceding the notice. Two separate transactions, each involving 2,850 shares of common stock, were executed under the same 10b5-1 plan: one on August 31, 2026 generating gross proceeds of $207,475.16, and one on September 29, 2026 generating gross proceeds of $208,045.44. ANI Pharmaceuticals is headquartered at 104 Carnegie Center Drive, Suite 300, Princeton, New Jersey 08540, and the filing lists 22,959,488 total shares of common stock outstanding.

What Was Disclosed

A Form 144 notice filed October 29, 2026 discloses that ANI Pharmaceuticals officer Stephen Carey proposes to sell 8,550 shares of common stock with an aggregate market value of $613,120.50, under a Rule 10b5-1 plan adopted March 6, 2026.